
News|Articles|December 1, 2023
AAO 2023: Luminopia, first FDA-approved digital therapeutic for amblyopia
Author(s)David Hutton, Sheryl Stevenson
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Advertisement
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
3
PRIMA retinal implant restores vision in patients with advanced GA
4
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
5














































